We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection... read more Featured Products: More products

Download Mobile App




Rapid Diagnostic Tests for Chagas Disease Field Evaluated

By LabMedica International staff writers
Posted on 08 Jan 2020
Chagas disease, caused by infection with the protozoan parasite Trypanosoma cruzi, is the neglected tropical disease exerting a highest burden in the Western hemisphere. More...
It is estimated that there are around seven million people affected worldwide, the majority of them living in Latin America where the insect vectors that transmit the infection are endemic.

Methodologies used to diagnose T. cruzi infection largely depend on the disease stage status. In the acute phase, the levels of parasitemia enable direct detection of the parasite either by parasitological or by molecular biology techniques. Parasitemia becomes low and intermittent in the chronic phase, but the acute infection triggered seroconversion and anti-T.cruzi specific immunoglobulins are detectable for years, so the chronic stage can be indirectly identified by serological methods.

A team of scientists led by those at the University of Barcelona (Barcelona, Spain) evaluate an alternative algorithm for the conclusive diagnosis of chronic Chagas disease based on the use of rapid diagnostic tests (RDTs) in a field study made in the Chaco region of Bolivia. Enrollment was prospectively offered to all patients >1 year old that had not been previously treated for T. cruzi infection. The team used the Wiener recombinant and Wiener lysate antigen ELISA tests (Wiener Laboratorios, Buenos Aires, Argentina) as described previously. In case of discordance between them, a third ELISA test was used (Chagatek, Laboratorio Lemos, Buenos Aires, Argentina). Sera were obtained by centrifugation of coagulated whole blood obtained by venous puncture.

The scientists also used the RDTs: Chagas Stat-Pak (CSP; Chembio Inc., Medford, NY, USA) and Chagas Detect Plus (CDP; InBIOS International Inc., Seattle, WA, USA). In case of discordance between them, Wiener Laboratorios’ WL-Check RDT kit was used. All three RDTs were performed simultaneously with a tiny volume of whole blood obtained by finger prick. Study sampling and testing were made between April 2018 and August 2018. Upon applying inclusion and exclusion criteria, 685 subjects were finally included.

Overall, prevalence of Chagas disease in the population under study was determined to be 44.4%. There were 27 samples with discordant results that were subjected to a third ELISA (Chagatek), which yielded nine positive and 18 negative determinations. When comparing head-to-head the level of agreement between the two main RDTs (CSP and CDP), it appeared that both coincided in 93.1% of their determinations. The use of the third RDT (WL-Check) helped to resolve 47 discordant results: 39 of them were determined to be negative and eight were positive. In comparison to the ELISAs algorithm, the combined use of the RDTs provided a sensitivity of 97.7% and a specificity of 96.1%.

The authors concluded that their results support the use of RDTs for the diagnosis of chronic Chagas disease in the studied region, and encourage their evaluation in other regions of Bolivia and other endemic countries. The study was published on December 19, 2019 in the journal PLOS Neglected Tropical Diseases.

Related Links:
University of Barcelona
Wiener Laboratorios
Laboratorio Lemos
Chembio Inc
InBIOS International Inc



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Specimen Radiography System
TrueView 200 Pro
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.